See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Collegium Pharmaceutical, Inc. (COLL) - free report >>
Corbus Pharmaceuticals Holdings, Inc. (CRBP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Collegium Pharmaceutical, Inc. (COLL) - free report >>
Corbus Pharmaceuticals Holdings, Inc. (CRBP) - free report >>
Image: Bigstock
Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session
Collegium Pharmaceutical, Inc. (COLL - Free Report) was a big mover last session, as the company saw its shares rise 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.44 to $10.98 in the past one-month time frame.
The move came after the company signed a value-based contract with Cigna Corporation regarding its Xtampza ER.
The company has seen one positive estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Collegium Pharmaceutical. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Collegium Pharmaceutical currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Collegium Pharmaceutical, Inc. Price
Collegium Pharmaceutical, Inc. Price | Collegium Pharmaceutical, Inc. Quote
A better-ranked stock in the Medical - Drugs industry is Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is COLL going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>